Evidence map›Paper›PMID 40232412›Full record

ReviewCellular and molecular life sciences : CMLS2025

Research progress on circular RNA in the regulation of drug resistance in genitourinary cancers.

Peng-Cheng Hu, Jia-Tao Yao, Ke-Jie Wang, Sha-Zhou Ye, Xiang-Yu Meng, Hai-Chao Chen, Rui Yu, Qi Ma

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peng-Cheng HuHealth Science Center, Ningbo University, Ningbo, 315101, Zhejiang, China.
Jia-Tao YaoHealth Science Center, Ningbo University, Ningbo, 315101, Zhejiang, China.
Ke-Jie WangTranslational Research Laboratory for Urology, The First Affiliated Hospital of Ningbo University, #59 Liuting Street, Ningbo, 315010, Zhejiang, China.
Sha-Zhou YeTranslational Research Laboratory for Urology, The First Affiliated Hospital of Ningbo University, #59 Liuting Street, Ningbo, 315010, Zhejiang, China.
Xiang-Yu MengTranslational Research Laboratory for Urology, The First Affiliated Hospital of Ningbo University, #59 Liuting Street, Ningbo, 315010, Zhejiang, China.
Hai-Chao ChenDepartment of Urology, The First Affiliated Hospital of Ningbo University, #59 Liuting Street, Ningbo, 315010, Zhejiang, China. fychenhaichao@nbu.edu.cn.
Rui YuDepartment of Biochemistry and Molecular Biology, Zhejiang Key Laboratory of Pathophysiology, Health Science Center, Ningbo University, #818 Fenghua Road, Ningbo, 315211, Zhejiang, China. yurui@nbu.edu.cn.
Qi MaComprehensive Genitourinary Cancer Center, The First Affiliated Hospital of Ningbo University, #59 Liuting Street, Ningbo, 315010, Zhejiang, China. fyymaqi@nbu.edu.cn.ORCID http://orcid.org/0000-0002-5350-0362

Funding

Natural Science Foundation of Ningbo Municipality no.2024J342Natural Science Foundation of Ningbo Municipality no.2024J343Natural Science Foundation of Zhejiang Province LY20H050002
6 · The paper itself

Abstract

In recent years, significant progress has been made in the management of genitourinary cancers, primarily due to advancements in surgical techniques, the emergence of targeted therapy and immunotherapy, and the refinement of chemotherapy agents. However, despite the expanding arsenal of treatment modalities, some patients still face challenges associated with drug resistance, which hinders efforts to improve survival rates. Circular RNAs (circRNAs) are covalently closed RNA molecules with a stable structure and a unique ability to form reverse splicing loops. Increasing evidence suggests that abnormal expression of circRNAs is significantly correlated with the occurrence of genitourinay cancers, indicating their potentials as diagnostic and prognostic biomarkers, as well as new targets for treatment. Although research on circRNAs in genitourinary cancers has progressed, it is still in the preliminary stage. This review summarizes the properties and functions of circRNAs, focusing on their molecular and cellular mechanisms involved in mediating cancer-related drug resistance in the genitourinary system, including autophagy, epithelial-mesenchymal transition, and glycolysis, etc. The clinical potential of circRNAs in regulating drug resistance is also carefully discussed.

Indexed as

Drug Resistance, NeoplasmRNA, CircularUrogenital NeoplasmsAnimalsAntineoplastic AgentsBiomarkers, TumorEpithelial-Mesenchymal TransitionGene Expression Regulation, NeoplasticHumansAntineoplastic AgentsBiomarkers, TumorRNA, CircularBladder cancerCircular RNADrug resistanceProstate cancerRenal cell carcinoma

Identifiers

PMID40232412
PMCPMC12000500

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.